← Human Trials & Peer-Reviewed Studies
Effect of L-carnitine supplementation on lipid profile and apolipoproteins in children on hemodialysis: a randomized placebo-controlled clinical trial
Plain-language guide to PMID 34037885 (2021): placebo-controlled randomized controlled trial study of L-Carnitine in 30 children.
Key Facts
- PMID
- 34037885
- Journal
- Pediatric nephrology (Berlin, Germany)
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Hamedi-Kalajahi F et al. (6 authors)
- DOI
- 10.1007/s00467-021-05080-1
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of L-Carnitine, published as a randomized controlled trial.
One-way repeated measures analysis was used to evaluate the effects of L-carnitine supplementation.
Why It Was Studied
Dyslipidemia is common in children with CKD and is considered one of the major causes of CVD in these patients.
The researchers registered the present trial in the Iranian Registry of Clinical Trials website (available at: http://www.irct.ir , identifier: IRCT20170202032367N2).
Who Took Part
The study group was 30 children.
PubMed indexes the participants as children and teenagers.
A total of 30 children on hemodialysis (6-18 years) were enrolled and 24 completed the study.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got L-Carnitine and who got the comparison, which limits bias.
Some children received a placebo instead of L-Carnitine, giving a reference point.
Serum FC, total cholesterol (TC), LDL-C, HDL-C, TG, Apolipoprotein B (ApoB), and Apolipoprotein A1 (ApoA1) were determined at the baseline and after the intervention.
What Was Measured
The subject headings attached to it are Apolipoproteins, Carnitine, Dietary Supplements, Iran, Lipids, Renal Dialysis and Renal Insufficiency, Chronic.
Author keywords: Hemodialysis, Pediatrics and Stage 5 chronic kidney disease.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of L-Carnitine in 30 children.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2021 (Pediatric nephrology (Berlin, Germany)), a journal based in Germany.
More context: the L-Carnitine compound page, all human trials.
Our Notes on the Compound
L-Carnitine: An amino acid derivative that carries fatty acids into mitochondria for energy production.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.